Shingles Vaccine: Stroke Risk And Prevention

The Zostavax shingles vaccine has been linked to an increased risk of stroke, with some individuals experiencing debilitating side effects such as persistent shingles outbreaks, cardiovascular events, vision loss, and other infections and autoimmune disorders. However, studies have also shown that the shingles vaccine may reduce the risk of stroke in older adults by about 16%. This reduction in risk is thought to be due to the vaccine's ability to prevent shingles outbreaks, which are associated with an increased risk of stroke. As a result, the American Heart Association recommends the shingles vaccine for adults over 50 years of age to help reduce their risk of stroke.

Zostavax, a shingles vaccine, has been linked to strokes and other severe complications

One product liability lawsuit filed by a Utah woman claims that the side effects of the Zostavax vaccine caused her to suffer a stroke and left her with permanent vision loss, among other complications. The plaintiff, Roma Maurine Veater, alleges that Merck used an under-attenuated version of the live virus in the Zostavax vaccine, which can cause a reactivation of the herpes zoster virus, resulting in more persistent and severe shingles outbreaks. Veater received the Zostavax inoculation in September 2017 and shortly after, she suffered an abrupt onset of vertigo, vision loss, and nausea. She was hospitalized and diagnosed with acute ischemic stroke, which she blames on the side effects of the shingles vaccine.

Zostavax has been linked to other severe complications, including persistent shingles outbreaks, other infections, and autoimmune disorders. In addition, thousands of Zostavax lawsuits have been filed against the drug's manufacturer, Merck & Co. Inc. Pharmaceuticals, since 2016. The plaintiffs in these lawsuits allege that, in addition to the above complications, the medication causes neurological diseases or disorders (such as brain inflammation and brain damage), spinal cord inflammation, liver damage and liver failure, and postherpetic neuralgia.

While Zostavax has been linked to an increased risk of stroke and other severe complications, it is important to note that the newer vaccine, Shingrix, has proven to be much more effective in preventing shingles. As a result, Zostavax is no longer available in the United States as of November 2020.

The Zoster Vaccine Live helps prevent shingles and reduces the risk of shingles by about 51%

The Zoster Vaccine Live (ZVL), also known as Zostavax, helps prevent shingles and reduces the risk of developing the disease by about 51%. ZVL is a live vaccine designed to vaccinate older adults against shingles, a painful condition that causes skin blisters and can lead to serious complications.

Shingles is caused by the reactivation of the chickenpox virus, which remains dormant in the body after a person recovers from chickenpox. The risk of developing shingles increases with age, and about one in three people who have had chickenpox will develop shingles in their lifetime.

ZVL was the first shingles vaccine approved in the U.S. and was widely used after its introduction in 2006. However, it has since been replaced by a newer version, the Adjuvanted, Non-Live Recombinant Shingles Vaccine (also known as Shingrix), which confers greater protection. Zostavax is no longer available in the United States as of November 2020.

While ZVL is effective in reducing the risk of shingles, its protection declines with age. It is about 64% effective in people aged 60-69, 41% effective for those aged 70-79, and about 18% effective in individuals 80 years or older.

In addition to preventing shingles, ZVL may also offer protection against stroke. A study presented at the American Stroke Association's 2020 International Stroke Conference found that ZVL lowered the risk of stroke by about 16% in older adults. The vaccine was found to be particularly effective in individuals aged 66 to 79 years, and it reduced the risk of ischemic and hemorrhagic strokes.

While ZVL has been linked to a reduced risk of shingles and potentially stroke, there have been reports of side effects and complications associated with the vaccine. Some individuals have experienced persistent and severe shingles outbreaks, as well as other infections and autoimmune disorders, shortly after receiving ZVL. It is important to weigh the benefits and risks of any vaccine and consult with a healthcare provider to determine the most appropriate course of action.

A 2017 study showed that shingles increases the risk of stroke by 35%

The study's findings have important implications for clinical practice and patient education. Firstly, it highlights the need for physicians to be aware of the elevated risk of stroke in patients with shingles. This knowledge can inform clinical decision-making and patient management, ensuring that healthcare providers can closely monitor and proactively manage patients' cardiovascular health. Additionally, patient education plays a crucial role. Informing patients about the increased risk of stroke empowers them to take proactive measures to protect their health. This may include seeking medical attention promptly if they experience any stroke-like symptoms and adopting lifestyle changes to reduce their risk.

While the study provides valuable insights, it is essential to approach the findings with a critical eye. The study had a relatively small sample size compared to more recent studies, which may impact the generalizability of the results. Additionally, the study design may have limitations, as it relied solely on medical records to identify diagnoses. Further research, including larger, prospective studies, is necessary to validate these findings and establish a causal relationship between shingles and stroke.

Furthermore, the study's results underscore the importance of shingles vaccination in reducing the risk of shingles and its associated complications. The vaccine not only protects against the painful rash caused by shingles but also potentially lowers the chances of long-term cardiovascular events, including stroke. The availability of effective vaccines, such as the Adjuvanted, Non-Live Recombinant Shingles Vaccine, recommended by the CDC, offers a promising strategy to mitigate the risk of shingles and its associated impact on cardiovascular health.

Shingles is caused by the same virus responsible for chickenpox, which can lie dormant in the body for years

Shingles is a viral infection caused by the varicella-zoster virus, which is the same virus responsible for chickenpox. After a person recovers from chickenpox, the virus remains dormant in the body, hiding in nerve cells near the spinal cord. It can remain inactive for years, sometimes becoming active again in adulthood, manifesting as shingles.

Shingles is characterised by a painful rash that typically appears as a stripe of blisters wrapping around one side of the torso. It can also occur on the face, eyes, mouth, and ears. The pain associated with shingles can be intense and may precede the appearance of the rash. The virus can be reactivated due to various factors, including stress, weakened immunity, certain diseases, and medications.

Shingles is not life-threatening, but it can be extremely painful and may lead to serious complications, such as postherpetic neuralgia, vision loss, and neurological problems. Vaccines are available to prevent shingles and lower the risk of associated complications. While the vaccines do not guarantee 100% protection, they significantly reduce the likelihood of developing shingles and lessen the severity of the disease if contracted.

While shingles itself is not caused by a stroke, there is a link between shingles and an increased risk of stroke. Research suggests that the inflammation caused by the virus may contribute to the elevated stroke risk. The shingles vaccine may play a role in reducing this risk, with studies indicating a potential reduction of up to 20% in individuals aged 66 to 79 years.

The American Heart Association recommends adults over 50 get the shingles vaccine to help prevent strokes

The American Heart Association recommends that adults over 50 get the shingles vaccine, as it may help prevent strokes. Shingles is a viral infection caused by the chickenpox virus, which lies dormant in the body and can reactivate later in life, causing a painful rash with blisters. The risk of developing shingles increases with age, and it is linked to an increased risk of stroke.

The Zoster Vaccine Live (ZVL) is a type of shingles vaccination that has been found to reduce the risk of stroke in older adults. A study presented at the American Stroke Association's International Stroke Conference in 2020 found that the ZVL vaccine lowered the risk of stroke by about 16% in adults over the age of 66. The risk of ischemic stroke was lowered by about 18%, and the risk of hemorrhagic stroke was lowered by about 12%. The vaccine's protection was strongest among people aged 66 to 79, with a nearly 20% reduction in stroke risk compared to a 10% reduction for those 80 and older.

The ZVL vaccine is effective in preventing shingles, reducing the risk by about 51%. However, its effectiveness decreases with age, dropping to about 18% in people 80 years and older. Despite this, the vaccine can still provide some protection against shingles and reduce the risk of stroke in older adults.

While the ZVL vaccine has been largely replaced by the newer Shingrix vaccine, which is more than 90% effective in preventing shingles, the American Heart Association's recommendation for adults over 50 to get vaccinated against shingles remains important for stroke prevention. Further studies are needed to confirm the link between the ZVL vaccine and stroke reduction and to determine the association between the Shingrix vaccine and stroke risk.

In conclusion, the American Heart Association's recommendation for adults over 50 to receive the shingles vaccine is supported by research indicating a reduced risk of stroke in this age group. By getting vaccinated, individuals can lower their risk of developing shingles and potentially reduce their risk of stroke.

Frequently asked questions